Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Towards Foundation Models with Native Multi-Agent Intelligence
arXiv:2512.08743v1 Announce Type: new Abstract: Foundation models (FMs) are increasingly assuming the role of the "brain" of AI agents. While recent efforts have begun to equip FMs with native single-agent abilities -- such as GUI interaction or integrated tool use -- we argue that the next frontier is endowing FMs with native multi-agent intelligence. We identify four core capabilities of FMs in multi-agent contexts: understanding, planning, efficient communication, and adaptation. Contrary to
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer
Discov Oncol. 2025 Jul 23;16(1):1391. doi: 10.1007/s12672-025-03243-2.ABSTRACTWe developed the first multi-omics prognostic signature integrating 19 programmed cell death (PCD) pathways and organelle functions (mitochondria, lysosomes, Golgi apparatus) to predict prognosis and immunotherapy response in non-small cell lung cancer (NSCLC). (2) Methods: By combining single-cell RNA-seq, bulk transcriptomics, and deep neural networks (DNN), we identified a 23-gene signature validated across four coh
A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer
Discov Oncol. 2025 Jul 23;16(1):1391. doi: 10.1007/s12672-025-03243-2.
ABSTRACT
We developed the first multi-omics prognostic signature integrating 19 programmed cell death (PCD) pathways and organelle functions (mitochondria, lysosomes, Golgi apparatus) to predict prognosis and immunotherapy response in non-small cell lung cancer (NSCLC). (2) Methods: By combining single-cell RNA-seq, bulk transcriptomics, and deep neural networks (DNN), we identified a 23-gene signature validated across four cohorts (AUC 0.696–0.812). Conducted MR analysis to explore causal links between signature genes and NSCLC incidence, providing biological insights. (3) Results: A prognostic signature was developed, including 23 prognostic genes related to 19 PCD patterns and three organelle functions. The signature demonstrated powerful performance in predicting NSCLC prognosis, immune in-filtration, and therapeutic response. Established DNN models showed high value in predicting risk score groupings of NSCLC. MR analysis for combined SNP information of the 23 prognostic genes suggested a link to the high incidence of NSCLC. Individual MR analysis showed that HIF1A and SQLE expression had a causal effect on NSCLC incidence. (4) Conclusion: This signature stratifies high-risk patients with immunosuppressive microenvironments and predicts enhanced sensitivity to gemcitabine and PD-1 inhibitors, offering a roadmap for personalized NSCLC management.
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-025-03243-2.
PMID:40699399 | PMC:PMC12287486 | DOI:10.1007/s12672-025-03243-2
-
Cell
-
Systems-level immunomonitoring in children with solid tumors to enable precision medicine
In a population-based cohort of 191 children with diverse solid tumors, systems-level analyses unravel immune variation with age and tumor type and provide a reference for future precision immunotherapies tailored for the evolving immune systems of children.
Systems-level immunomonitoring in children with solid tumors to enable precision medicine
-
Nature Biotechnology - Issue - nature.com science feeds
-
Targeted genome editing with a DNA-dependent DNA polymerase and exogenous DNA-containing templates
Nature Biotechnology, Published online: 14 September 2023; doi:10.1038/s41587-023-01947-wA DNA polymerase editing system offers advantages over prime editing.
Targeted genome editing with a DNA-dependent DNA polymerase and exogenous DNA-containing templates
Nature Biotechnology, Published online: 14 September 2023; doi:10.1038/s41587-023-01947-w
A DNA polymerase editing system offers advantages over prime editing.-
Nature Biotechnology - Issue - nature.com science feeds
-
Author Correction: An engineered influenza virus to deliver antigens for lung cancer vaccination
Nature Biotechnology, Published online: 13 July 2023; doi:10.1038/s41587-023-01884-8Author Correction: An engineered influenza virus to deliver antigens for lung cancer vaccination
Author Correction: An engineered influenza virus to deliver antigens for lung cancer vaccination
Nature Biotechnology, Published online: 13 July 2023; doi:10.1038/s41587-023-01884-8
Author Correction: An engineered influenza virus to deliver antigens for lung cancer vaccination-
Nature Biotechnology - Issue - nature.com science feeds
-
An engineered influenza virus to deliver antigens for lung cancer vaccination
Nature Biotechnology, Published online: 25 May 2023; doi:10.1038/s41587-023-01796-7A cancer vaccine is delivered to the lung by an engineered attenuated influenza virus.
An engineered influenza virus to deliver antigens for lung cancer vaccination
Nature Biotechnology, Published online: 25 May 2023; doi:10.1038/s41587-023-01796-7
A cancer vaccine is delivered to the lung by an engineered attenuated influenza virus.